Dr. Ruolan Han joined OncoNano in 2021 as Vice President of Nonclinical and Translational Medicine. Ruolan has more than 15 years of broad-based experience in cancer research and preclinical drug development. She has a successful track record of development and execution of strategies across many areas of nonclinical and translational research including transitioning pipeline compounds from pre-IND studies to early-phase clinical trials. Prior to joining OncoNano, Roulan led nonclinical and translational programs at Salarius Pharmaceuticals and Beta Cat Pharmaceuticals/Iterion Therapeutics. Ruolan received her bachelor’s degree in genetics from Fudan University and Doctor of Philosophy in pharmacology from the University of Rochester.